Key result
Laparoscopic aortobifemoral bypass yields ~82% 10-year primary patency in advanced aortoiliac occlusive disease.
Why the study?
Laparoscopic aortobifemoral bypass is a minimally invasive option for extensive aortoiliac occlusive disease, but data on its long-term durability are limited.
What are the 10-year patency, survival, and complication outcomes of laparoscopic aortobifemoral bypass in patients with TASC II C and D aortoiliac occlusive disease?
Cohort (n=20)
No
What are the 10-year patency, survival, and complication outcomes of laparoscopic aortobifemoral bypass in patients with TASC II C and D aortoiliac occlusive disease?
Laparoscopic aortobifemoral bypass demonstrates durable 10-year primary (82.0%) and secondary (88.0%) patency rates comparable to open repair, offering a viable minimally invasive surgical alternative for complex TASC II C and D aortoiliac occlusive disease unsuitable for endovascular therapy.
Answers are grounded in this paper and cite their sources.
Supports laparoscopic aortobifemoral bypass durability in TASC C/D AIOD; leaves open randomized comparison with open repair.
Purpose: Laparoscopic aortobifemoral bypass (LABF) is a minimally invasive option for extensive aortoiliac occlusive disease (AIOD), but data on its long-term durability are limited. We aimed to evaluate the 10-year outcomes of LABF for patients with TransAtlantic Inter-Society Consensus (TASC) II C and D lesions. Methods: We retrospectively analyzed a prospectively maintained database of 20 patients who underwent LABF for TASC II C or D AIOD at a single tertiary center between January 2004 and December 2012. Primary endpoints were primary and secondary patency rates, survival, and postoperative complications. Results: The median patient age was 65 years, and 18 (90.0%) were male. TASC II D lesions were present in 18 patients (90.0%). There was one perioperative death (5.0%). Kaplan-Meier analysis revealed primary patency rates of 94.7%, 88.8%, 82.0%, and 82.0% at 1, 3, 5, and 10 years, respectively. The 10-year secondary patency rate was 88.0%. Reintervention was required in 2 patients (10.0%) during follow-up. Conclusion: LABF provides excellent long-term patency rates comparable to open repair for complex AIOD. With careful patient selection, LABF represents a safe, feasible, and durable minimally invasive alternative, particularly for patients unsuitable for endovascular therapy.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2026) conducted a cohort in Extensive aortoiliac occlusive disease (AIOD) classified as TASC II C or D (n=20). Laparoscopic aortobifemoral bypass (LABF, including totally laparoscopic, laparoscopy-assisted, and robot-assisted approaches) was evaluated on 10-year primary patency rate. Laparoscopic aortobifemoral bypass achieved primary patency rates of 94.7% at 1 year and 82.0% at 10 years, with a 10-year secondary patency rate of 88.0% in patients with TASC II C/D AIOD.
Synapse has enriched 10 related papers. Consider them for comparative context: